Novartis AG (NVS)
NYSE · Healthcare · Drug Manufacturers - General
$140.93−0.05%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $268B
- P/E (trailing)
- 21.3
- Forward P/E
- 14.3
- Dividend yield
- 3.4%
- 52-week range
- $121.57 – $170.46
- 52-week change
- +7.18%
- EPS (trailing)
- $6.62
- Analyst rating
- 2.6 Hold
- Next earnings
- Oct 27, 2026
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD).
Headquarters: Basel, Switzerland · 75,267 employees · novartis.com